LAVA Therapeutics N.V. (LVTX)
NASDAQ: LVTX · Real-Time Price · USD
1.030
+0.041 (4.16%)
At close: Dec 20, 2024, 4:00 PM
1.090
+0.060 (5.83%)
After-hours: Dec 20, 2024, 7:32 PM EST
LAVA Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for LAVA Therapeutics stock have an average target of 3.33, with a low estimate of 2.00 and a high estimate of 6.00. The average target predicts an increase of 223.30% from the current stock price of 1.03.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for LVTX stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $6 → $2 | Strong Buy | Maintains | $6 → $2 | +94.17% | Dec 20, 2024 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $11 → $2 | Buy → Hold | Downgrades | $11 → $2 | +94.17% | Dec 12, 2024 |
| JMP Securities | JMP Securities | Buy → Hold Downgrades $6 | Buy → Hold | Downgrades | $6 | +482.52% | Dec 11, 2024 |
| JMP Securities | JMP Securities | Buy Reiterates $6 | Buy | Reiterates | $6 | +482.52% | Aug 21, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $6 | Strong Buy | Reiterates | $6 | +482.52% | Jun 28, 2024 |
Financial Forecast
Revenue This Year
3.57M
from 6.77M
Decreased by -47.32%
Revenue Next Year
n/a
from 3.57M
EPS This Year
-1.17
from -1.57
EPS Next Year
-1.98
from -1.17
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 7.3M | n/a | n/a | |||
| Avg | 3.6M | n/a | n/a | |||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 8.5% | - | - | |||
| Avg | -47.3% | - | - | |||
| Low | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -1.14 | -1.70 | -1.61 | |||
| Avg | -1.17 | -1.98 | -1.92 | |||
| Low | -1.18 | -2.21 | -2.20 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.